Chronic hepatitis C: Portrait of a silent epidemic and the etiologic agent

  • Ralf Bartenschlager
  • Gang Long
  • Darius Moradpour
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)


Chronic liver disease caused by infection with the hepatitis C virus (HCV) is an important medical problem. Although primary infection usually is mild, and often asymptomatic, in the vast majority of cases HCV establishes persistence that in the course of one or several decades may result in chronic liver diseases including liver cirrhosis and hepatocellular carcinoma. Therapeutic options are limited and a vaccine to prevent HCV infection is not in sight. Diagnostic tests to detect HCV-containing blood products have become available after the first molecular cloning of the viral genome. This achievement also opened the field for studies of the viral replication cycle as well as the development of selective antiviral drugs. HCV is a hepatotropic flavivirus which has several remarkable properties. Among these are the potent inhibition of the induction phase of the innate antiviral response, the high genomic plasticity and the unusual strategy of virus particle assembly that occurs in close association with lipid droplets and the very-low-density lipoprotein production pathway. This chapter will briefly summarise some old and new aspects of chronic hepatitis C and of the pathogen responsible for this disease.


Chronic Hepatitis Lipid Droplet Viral Replication Cycle Virus CORE Protein Alternate Read Frame 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davis GL, Albright JE, Cook SF, Rosenberg DM (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331–338PubMedCrossRefGoogle Scholar
  2. 2.
    Williams R (2006) Global challenges in liver disease. Hepatology 44: 521–526PubMedCrossRefGoogle Scholar
  3. 3.
    Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558–567PubMedCrossRefGoogle Scholar
  4. 4.
    Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP (2004) Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 351: 760–768PubMedCrossRefGoogle Scholar
  5. 5.
    Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W (2000) The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355: 887–891PubMedCrossRefGoogle Scholar
  6. 6.
    Prati D (2006) Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 45: 607–616PubMedCrossRefGoogle Scholar
  7. 7.
    Ross RS, Viazov S, Gross T, Hofmann F, Seipp HM, Roggendorf M (2000) Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients. N Engl J Med 343: 1851–1854PubMedCrossRefGoogle Scholar
  8. 8.
    Forns X, Martinez-Bauer E, Feliu A, Garcia-Retortillo M, Martin M, Gay E, Navasa M, Sanchez-Tapias JM, Bruguera M, Rodes J (2005) Nosocomial transmission of HCV in the liver unit of a tertiary care center. Hepatology 41: 115–122PubMedCrossRefGoogle Scholar
  9. 9.
    Macedo dO, White KL, Leschinsky DP, Beecham BD, Vogt TM, Moolenaar RL, Perz JF, Safranek TJ (2005) An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 142: 898–902Google Scholar
  10. 10.
    Conry CC, Van Raden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334: 1691–1696CrossRefGoogle Scholar
  11. 11.
    Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, Alter MJ (2005) Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 192: 1880–1889PubMedCrossRefGoogle Scholar
  12. 12.
    Hoofnagle JH (2002) Course and outcome of hepatitis C. Hepatology 36: S21–S29PubMedCrossRefGoogle Scholar
  13. 13.
    Alter HJ (2005) HCV natural history: the retrospective and prospective in perspective. J Hepatol 43: 550–552PubMedCrossRefGoogle Scholar
  14. 14.
    Seeff LB (2002) Natural history of chronic hepatitis C. Hepatology 36: S35–S46PubMedCrossRefGoogle Scholar
  15. 15.
    Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, Johnson LD, Lee SR, Kaplan EL (2000) 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132: 105–111PubMedGoogle Scholar
  16. 16.
    Tong MJ, El Farra NS, Reikes AR, Co RL (1995) Clinical outcomes after transfusionassociated hepatitis C. N Engl J Med 332: 1463–1466PubMedCrossRefGoogle Scholar
  17. 17.
    Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340: 1228–1233PubMedCrossRefGoogle Scholar
  18. 18.
    Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H (2005) Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 43: 590–598PubMedCrossRefGoogle Scholar
  19. 19.
    Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R (2007) Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol 47: 31–36PubMedCrossRefGoogle Scholar
  20. 20.
    El Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36: S74–S83PubMedCrossRefGoogle Scholar
  21. 21.
    Moradpour D, Blum HE (2005) Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 17: 477–483PubMedCrossRefGoogle Scholar
  22. 22.
    van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, Maniloff J, Mayo MA, McGeoch DJ, Pringle CR (2000) Virus Taxonomy: The VIIth Report of the International Committee on Taxonomy of Viruses. Academic Press, San DiegoGoogle Scholar
  23. 23.
    Pawlotsky JM (2003) Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin Liver Dis 7: 45–66PubMedCrossRefGoogle Scholar
  24. 24.
    Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143: 2493–2503PubMedCrossRefGoogle Scholar
  25. 25.
    Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391–2399PubMedCrossRefGoogle Scholar
  26. 26.
    Lohmann V, Roos A, Korner F, Koch JO, Bartenschlager R (2000) Biochemical and structural analysis of the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. J Viral Hepat 7: 167–174PubMedCrossRefGoogle Scholar
  27. 27.
    You S, Stump DD, Branch AD, Rice CM (2004) A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 78: 1352–1366PubMedCrossRefGoogle Scholar
  28. 28.
    Friebe P, Boudet J, Simorre JP, Bartenschlager R (2005) Kissing-loop interaction in the 3’ end of the hepatitis C virus genome essential for RNA replication. J Virol 79: 380–392PubMedCrossRefGoogle Scholar
  29. 29.
    Bartenschlager R, Frese M, Pietschmann T (2004) Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63: 71–180PubMedCrossRefGoogle Scholar
  30. 30.
    Penin F (2003) Structural biology of hepatitis C virus. Clin Liver Dis 7: 1–21, viiPubMedCrossRefGoogle Scholar
  31. 31.
    Appel N, Schaller T, Penin F, Bartenschlager R (2006) From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 281: 9833–9836PubMedCrossRefGoogle Scholar
  32. 32.
    Tellinghuisen TL, Evans MJ, von Hahn T, You S, Rice CM (2007) Studying hepatitis C virus: making the best of a bad virus. J Virol 81: 8853–8867PubMedCrossRefGoogle Scholar
  33. 33.
    Santolini E, Migliaccio G, La MN (1994) Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol 68: 3631–3641PubMedGoogle Scholar
  34. 34.
    McLauchlan J, Lemberg MK, Hope G, Martoglio B (2002) Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 21: 3980–3988PubMedCrossRefGoogle Scholar
  35. 35.
    Klein KC, Dellos SR, Lingappa JR (2005) Identification of residues in the hepatitis C virus core protein that are critical for capsid assembly in a cell-free system. J Virol 79: 6814–6826PubMedCrossRefGoogle Scholar
  36. 36.
    Klein KC, Polyak SJ, Lingappa JR (2004) Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly. J Virol 78: 9257–9269PubMedCrossRefGoogle Scholar
  37. 37.
    Boulant S, Targett-Adams P, McLauchlan J (2007) Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 88: 2204–2213PubMedCrossRefGoogle Scholar
  38. 38.
    Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9: 1089–1097PubMedCrossRefGoogle Scholar
  39. 39.
    Goffard A, Dubuisson J (2003) Glycosylation of hepatitis C virus envelope proteins. Biochimie 85: 295–301PubMedCrossRefGoogle Scholar
  40. 40.
    Deleersnyder V, Pillez A, Wychowski C, Blight K, Xu J, Hahn YS, Rice CM, Dubuisson J (1997) Formation of native hepatitis C virus glycoprotein complexes. J Virol 71: 697–704PubMedGoogle Scholar
  41. 41.
    Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79: 8400–8409PubMedCrossRefGoogle Scholar
  42. 42.
    Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M (1991) Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180: 842–848PubMedCrossRefGoogle Scholar
  43. 43.
    Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75: 5703–5710PubMedCrossRefGoogle Scholar
  44. 44.
    Callens N, Ciczora Y, Bartosch B, Vu-Dac N, Cosset FL, Pawlotsky JM, Penin F, Dubuisson J (2005) Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol 79: 15331–15341PubMedCrossRefGoogle Scholar
  45. 45.
    Troesch M, Meunier I, Lapierre P, Lapointe N, Alvarez F, Boucher M, Soudeyns H (2006) Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352: 357–367PubMedCrossRefGoogle Scholar
  46. 46.
    Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, Bartenschlager R (2007) Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 46: 330–338PubMedCrossRefGoogle Scholar
  47. 47.
    Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J (2002) Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 76: 3720–3730PubMedCrossRefGoogle Scholar
  48. 48.
    Griffin S, Clarke D, McCormick C, Rowlands D, Harris M (2005) Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. J Virol 79: 15525–15536PubMedCrossRefGoogle Scholar
  49. 49.
    Griffin SD, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ (2004) A conserved basic loop in hepatitis C virus p7 protein is required for amantadinesensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 85: 451–461PubMedCrossRefGoogle Scholar
  50. 50.
    Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 535: 34–38PubMedCrossRefGoogle Scholar
  51. 51.
    Sakai A, Claire MS, Faulk K, Govindarajan S, Emerson SU, Purcell RH, Bukh J (2003) The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 100: 11646–11651PubMedCrossRefGoogle Scholar
  52. 52.
    Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110–113PubMedCrossRefGoogle Scholar
  53. 53.
    Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T (2007) Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 3: 962–971CrossRefGoogle Scholar
  54. 54.
    Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM (2007) Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 81: 8374–8383PubMedCrossRefGoogle Scholar
  55. 55.
    Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972–1974PubMedCrossRefGoogle Scholar
  56. 56.
    Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277: 570–574PubMedCrossRefGoogle Scholar
  57. 57.
    Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L, Bonelli F, Orru S, Narjes F, Steinkuhler C (2001) Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol 75: 9939–9946PubMedCrossRefGoogle Scholar
  58. 58.
    Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM (1993) A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci USA 90: 10583–10587PubMedCrossRefGoogle Scholar
  59. 59.
    Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K (1993) Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol 67: 4665–4675PubMedGoogle Scholar
  60. 60.
    Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM (2006) Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442: 831–835PubMedCrossRefGoogle Scholar
  61. 61.
    Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O’Malley ET (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87: 343–355PubMedCrossRefGoogle Scholar
  62. 62.
    Love RA, Parge HE, Wickersham JA, Hostomsky Z, Habuka N, Moomaw EW, Adachi T, Hostomska Z (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87: 331–342PubMedCrossRefGoogle Scholar
  63. 63.
    Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7: 1353–1363PubMedCrossRefGoogle Scholar
  64. 64.
    Wolk B, Sansonno D, Krausslich HG, Dammacco F, Rice CM, Blum HE, Moradpour D (2000) Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracyclineregulated cell lines. J Virol 74: 2293–2304PubMedCrossRefGoogle Scholar
  65. 65.
    Tai CL, Chi WK, Chen DS, Hwang LH (1996) The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J Virol 70: 8477–8484PubMedGoogle Scholar
  66. 66.
    Hugle T, Fehrmann F, Bieck E, Kohara M, Krausslich HG, Rice CM, Blum HE, Moradpour D (2001) The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 284: 70–81PubMedCrossRefGoogle Scholar
  67. 67.
    Lundin M, Monne M, Widell A, Von Heijne G, Persson MA (2003) Topology of the membrane-associated hepatitis C virus protein NS4B. J Virol 77: 5428–5438PubMedCrossRefGoogle Scholar
  68. 68.
    Gretton SN, Taylor AI, McLauchlan J (2005) Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci. J Gen Virol 86: 1415–1421PubMedCrossRefGoogle Scholar
  69. 69.
    Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K (2002) Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76: 5974–5984PubMedCrossRefGoogle Scholar
  70. 70.
    Yu GY, Lee KJ, Gao L, Lai MM (2006) Palmitoylation and polymerization of hepatitis C virus NS4B protein. J Virol 80: 6013–6023PubMedCrossRefGoogle Scholar
  71. 71.
    Brass V, Bieck E, Montserret R, Wolk B, Hellings JA, Blum HE, Penin F, Moradpour D (2002) An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 277: 8130–8139PubMedCrossRefGoogle Scholar
  72. 72.
    Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D, Blum HE, Bartenschlager R, Moradpour D (2004) Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 279: 40835–40843PubMedCrossRefGoogle Scholar
  73. 73.
    Appel N, Pietschmann T, Bartenschlager R (2005) Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol 79: 3187–3194PubMedCrossRefGoogle Scholar
  74. 74.
    Moradpour D, Evans MJ, Gosert R, Yuan Z, Blum HE, Goff SP, Lindenbach BD, Rice CM (2004) Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 78: 7400–7409PubMedCrossRefGoogle Scholar
  75. 75.
    Quintavalle M, Sambucini S, Di Pietro C, De Francesco R, Neddermann P (2006) The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J Virol 80: 11305–11312PubMedCrossRefGoogle Scholar
  76. 76.
    Quintavalle M, Sambucini S, Summa V, Orsatti L, Talamo F, De Francesco R, Neddermann P (2007) Hepatitis C virus NS5A is a direct substrate of casein kinase I-alpha, a cellular kinase identified by inhibitor affinity chromatography using specific NS5A hyperphosphorylation inhibitors. J Biol Chem 282: 5536–5544PubMedCrossRefGoogle Scholar
  77. 77.
    Neddermann P, Quintavalle M, Di Pietro C, Clementi A, Cerretani M, Altamura S, Bartholomew L, De Francesco R (2004) Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. J Virol 78: 13306–13314PubMedCrossRefGoogle Scholar
  78. 78.
    Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De FR, Rey FA (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96: 13034–13039PubMedCrossRefGoogle Scholar
  79. 79.
    Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6: 937–943PubMedCrossRefGoogle Scholar
  80. 80.
    Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, Shimotohno K (2005) Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19: 111–122PubMedCrossRefGoogle Scholar
  81. 81.
    Watashi K, Shimotohno K (2007) Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 17: 245–252PubMedCrossRefGoogle Scholar
  82. 82.
    Branch AD, Stump DD, Gutierrez JA, Eng F, Walewski JL (2005) The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis 25: 105–117PubMedCrossRefGoogle Scholar
  83. 83.
    McMullan LK, Grakoui A, Evans MJ, Mihalik K, Puig M, Branch AD, Feinstone SM, Rice CM (2007) Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci USA 104: 2879–2884PubMedCrossRefGoogle Scholar
  84. 84.
    Feinstone SM, Mihalik KB, Kamimura T, Alter HJ, London WT, Purcell RH (1983) Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun 41: 816–821PubMedGoogle Scholar
  85. 85.
    Bradley DW, McCaustland KA, Cook EH, Schable CA, Ebert JW, Maynard JE (1985) Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus. Gastroenterology 88: 773–779PubMedGoogle Scholar
  86. 86.
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791–796PubMedCrossRefGoogle Scholar
  87. 87.
    Yu X, Qiao M, Atanasov I, Hu Z, Kato T, Liang TJ, Zhou ZH (2007) Cryoelectron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 367: 126–134PubMedCrossRefGoogle Scholar
  88. 88.
    Kanto T, Hayashi N, Takehara T, Hagiwara H, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T (1994) Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. Hepatology 19: 296–302PubMedCrossRefGoogle Scholar
  89. 89.
    Prince AM, HuimaByron T, Parker TS, Levine DM (1996) Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 3: 11–17PubMedCrossRefGoogle Scholar
  90. 90.
    Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80: 2418–2428PubMedCrossRefGoogle Scholar
  91. 91.
    Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M Jr, Ye J (2007) Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 104: 5848–5853PubMedCrossRefGoogle Scholar
  92. 92.
    Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, Pol S, Brechot C, Paranhos-Baccala G, Lotteau V (2002) Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J Virol 76: 6919–6928PubMedCrossRefGoogle Scholar
  93. 93.
    Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX (1999) Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96: 12766–12771PubMedCrossRefGoogle Scholar
  94. 94.
    Nahmias Y, Casali M, Barbe L, Berthiaume F, Yarmush ML (2006) Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. Hepatology 43: 257–265PubMedCrossRefGoogle Scholar
  95. 95.
    Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21: 5017–5025PubMedCrossRefGoogle Scholar
  96. 96.
    Hahn T, Rice CM (2007) Hepatitis C virus entry. J Biol Chem 283: 3689–3693CrossRefGoogle Scholar
  97. 97.
    Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5: 453–463PubMedCrossRefGoogle Scholar
  98. 98.
    Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T (2007) The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol 81: 588–598PubMedCrossRefGoogle Scholar
  99. 99.
    Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, McKeating JA, Bieniasz PD, Rice CM (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801–805PubMedCrossRefGoogle Scholar
  100. 100.
    Meertens L, Bertaux C, Dragic T (2006) Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol 80: 11571–11578PubMedCrossRefGoogle Scholar
  101. 101.
    Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM (2006) Time-and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 80: 1734–1741PubMedCrossRefGoogle Scholar
  102. 102.
    Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, Moradpour D (2003) Identification of the hepatitis C virus RNA replication complex in huh-7 cells harboring subgenomic replicons. J Virol 77: 5487–5492PubMedCrossRefGoogle Scholar
  103. 103.
    Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T (1997) Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 94: 1200–1205PubMedCrossRefGoogle Scholar
  104. 104.
    Moradpour D, Englert C, Wakita T, Wands JR (1996) Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 222: 51–63PubMedCrossRefGoogle Scholar
  105. 105.
    Bartenschlager R (2006) Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol 9: 416–422PubMedCrossRefGoogle Scholar
  106. 106.
    Bukh J (2004) A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39: 1469–1475PubMedCrossRefGoogle Scholar
  107. 107.
    Alter HJ, Purcell RH, Holland PV, Popper H (1978) Transmissible agent in non-A, non-B hepatitis. Lancet 1: 459–463PubMedCrossRefGoogle Scholar
  108. 108.
    Hollinger FB, Gitnick GL, Aach RD, Szmuness W, Mosley JW, Stevens CE, Peters RL, Weiner JM, Werch JB, Lander JJ (1978) Non-A, non-B hepatitis transmission in chimpanzees: a project of the transfusion-transmitted viruses study group. Intervirology 10: 60–68PubMedCrossRefGoogle Scholar
  109. 109.
    Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, Jackson DR, April M, Barker LF, Pineda-Tamondong G (1978) Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1: 463–466PubMedCrossRefGoogle Scholar
  110. 110.
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362PubMedCrossRefGoogle Scholar
  111. 111.
    Yanagi M, Purcell RH, Emerson SU, Bukh J (1997) Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 94: 8738–8743PubMedCrossRefGoogle Scholar
  112. 112.
    Lanford RE, Bigger C (2002) Advances in model systems for hepatitis C virus research. Virology 293: 1–9PubMedCrossRefGoogle Scholar
  113. 113.
    Feinstone SM, Alter HJ, Dienes HP, Shimizu Y, Popper H, Blackmore D, Sly D, London WT, Purcell RH (1981) Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis 144: 588–598PubMedGoogle Scholar
  114. 114.
    Xie ZC, Riezu BJ, Lasarte JJ, Guillen J, Su JH, Civeira MP, Prieto J (1998) Transmission of hepatitis C virus infection to tree shrews. Virology 244: 513–520PubMedCrossRefGoogle Scholar
  115. 115.
    Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927–933PubMedCrossRefGoogle Scholar
  116. 116.
    Bartenschlager R (2005) The hepatitis C virus replicon system: from basic research to clinical application. J Hepatol 43: 210–216PubMedCrossRefGoogle Scholar
  117. 117.
    Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, Strand D, Bartenschlager R (2002) Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76: 4008–4021PubMedCrossRefGoogle Scholar
  118. 118.
    Ikeda M, Yi M, Li K, Lemon SM (2002) Selectable subgenomic and genomelength dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 76: 2997–3006PubMedCrossRefGoogle Scholar
  119. 119.
    Blight KJ, McKeating JA, Marcotrigiano J, Rice CM (2003) Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77: 3181–3190PubMedCrossRefGoogle Scholar
  120. 120.
    Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, Govindarajan S, Shapiro M, St Claire M, Bartenschlager R (2002) Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci USA 99: 14416–14421PubMedCrossRefGoogle Scholar
  121. 121.
    Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100: 7271–7276PubMedCrossRefGoogle Scholar
  122. 122.
    Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633–642PubMedCrossRefGoogle Scholar
  123. 123.
    Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, Nagayama K, Tanaka T, Wakita T (2001) Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 64: 334–339PubMedCrossRefGoogle Scholar
  124. 124.
    Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T (2003) Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125: 1808–1817PubMedCrossRefGoogle Scholar
  125. 125.
    Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, Lohmann V (2007) Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 81: 5270–5283PubMedCrossRefGoogle Scholar
  126. 126.
    Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102: 9294–9299PubMedCrossRefGoogle Scholar
  127. 127.
    Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux-Roels G et al (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 103: 3805–3809PubMedCrossRefGoogle Scholar
  128. 128.
    Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA et al (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623–626PubMedCrossRefGoogle Scholar
  129. 129.
    Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL et al (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103: 7408–7413PubMedCrossRefGoogle Scholar
  130. 130.
    Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM (2006) Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103: 2310–2315PubMedCrossRefGoogle Scholar
  131. 131.
    Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouille Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C (2007) Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol 88: 2495–2503PubMedCrossRefGoogle Scholar
  132. 132.
    Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R (2007) Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J Virol 81: 13168–13179PubMedCrossRefGoogle Scholar
  133. 133.
    Foy E, Wang C, Sumpter R, Ikeka M, Lemon SM, Gale M (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300: 1145–1148PubMedCrossRefGoogle Scholar
  134. 134.
    Hiscott J, Lacoste J, Lin R (2006) Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease. Biochem Pharmacol 72: 1477–1484PubMedCrossRefGoogle Scholar
  135. 135.
    Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM (2005) Immune evasion by hepatitis C virus NS3/4A proteasemediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 102: 2992–2997PubMedCrossRefGoogle Scholar
  136. 136.
    Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S, Wilkinson P, Julkunen I, Vitour D, Meurs E et al (2006) Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 80: 6072–6083PubMedCrossRefGoogle Scholar
  137. 137.
    Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437: 1167–1172PubMedCrossRefGoogle Scholar
  138. 138.
    Gale M Jr, Foy EM (2005) Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939–945PubMedCrossRefGoogle Scholar
  139. 139.
    Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946–952PubMedCrossRefGoogle Scholar
  140. 140.
    Pawlotsky JM, Germanidis G (1999) The non-structural 5A protein of hepatitis C virus. J Viral Hepat 6: 343–356PubMedCrossRefGoogle Scholar
  141. 141.
    Castera L, Pawlotsky JM (2005) Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. Med Gen Med 7: 39Google Scholar
  142. 142.
    Rockey DC, Bissell DM (2006) Noninvasive measures of liver fibrosis. Hepatology 43: S113–S120PubMedCrossRefGoogle Scholar
  143. 143.
    Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de LV, Marcellin P, Dhumeaux D, Trinchet JC et al (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41: 48–54PubMedCrossRefGoogle Scholar
  144. 144.
    Lewin M, Poujol-Robert A, Boelle PY, Wendum D, Lasnier E, Viallon M, Guechot J, Hoeffel C, Arrive L, Tubiana JM et al (2007) Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 46: 658–665PubMedCrossRefGoogle Scholar
  145. 145.
    Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147–1171PubMedCrossRefGoogle Scholar
  146. 146.
    Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967–972PubMedCrossRefGoogle Scholar
  147. 147.
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M et al (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609–2617PubMedCrossRefGoogle Scholar
  148. 148.
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Haussinger D, Herrmann E et al (2005) Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 129: 522–527Google Scholar
  149. 149.
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR et al (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130: 1086–1097PubMedCrossRefGoogle Scholar
  150. 150.
    Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C et al (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44: 97–103PubMedCrossRefGoogle Scholar
  151. 151.
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A et al (2007) Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357: 124–134PubMedCrossRefGoogle Scholar
  152. 152.
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR (2004) Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702–1708PubMedCrossRefGoogle Scholar
  153. 153.
    Muir AJ, Bornstein JD, Killenberg PG (2004) Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265–2271PubMedCrossRefGoogle Scholar
  154. 154.
    Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38: 639–644PubMedCrossRefGoogle Scholar
  155. 155.
    Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, Heathcote J, Edwards AM, McGilvray ID (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437–1444PubMedCrossRefGoogle Scholar
  156. 156.
    Paradis V, Asselah T, Dargere D, Ripault MP, Martinot M, Boyer N, Valla D, Marcellin P, Bedossa P (2006) Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology 130: 2189–2197PubMedCrossRefGoogle Scholar
  157. 157.
    Berg T, Pascu M, Moller B (2003) Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements. Hepatology 37: 1495–1496PubMedCrossRefGoogle Scholar
  158. 158.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982PubMedCrossRefGoogle Scholar
  159. 159.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965PubMedCrossRefGoogle Scholar
  160. 160.
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346–355PubMedGoogle Scholar
  161. 161.
    De Francesco R, Migliaccio G (2005) Challenges and successes in developing new therapies for hepatitis C. Nature 436: 953–960PubMedCrossRefGoogle Scholar
  162. 162.
    Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG et al (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426: 186–189PubMedCrossRefGoogle Scholar
  163. 163.
    Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij, McNair L, Purdy S, Kauffman R, Alam J et al (2006) Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebocontrolled, randomized study. Gastroenterology 131: 997–1002PubMedCrossRefGoogle Scholar
  164. 164.
    Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, Narjes F, Muraglia E, Paonessa G, Koch U et al (2003) In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77: 3669–3679PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2008

Authors and Affiliations

  • Ralf Bartenschlager
    • 1
  • Gang Long
    • 1
  • Darius Moradpour
    • 2
  1. 1.Department of Molecular VirologyUniversity of HeidelbergHeidelbergGermany
  2. 2.Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire VaudoisUniversity of LausanneLausanneSwitzerland

Personalised recommendations